To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

CDC's director, Rochelle Walensky – who is ... saying it will price its Arexvy shot somewhere between $200 and $295. Pfizer said its proposed range of $180 to $270 was subject to revision ...

In its Q3 results, GSK (GSK), the first to receive U.S. approval for an RSV vaccine in May 2023, said its Arexvy vaccine ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

The CDC recommends a single dose of either GSK's AREXVY, Moderna's mRESVIA or Pfizer's ABRYSVO for all adults 75 years and ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

“One factor that may help decrease the severity of this year’s RSV season is the availability of new RSV vaccines: Arexvy, ...

In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased ... Changes to ...